 Martin Krsak
Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonia, Viral | 5 | 2020 | 360 | 2.060 |
Why?
| | Coronavirus Infections | 5 | 2020 | 347 | 2.060 |
Why?
| | Prisons | 5 | 2020 | 57 | 1.750 |
Why?
| | Antibodies, Viral | 3 | 2021 | 561 | 1.720 |
Why?
| | Teicoplanin | 3 | 2021 | 17 | 1.550 |
Why?
| | Betacoronavirus | 5 | 2020 | 263 | 1.440 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2020 | 68 | 1.290 |
Why?
| | Pandemics | 5 | 2020 | 1434 | 1.290 |
Why?
| | Prisoners | 2 | 2020 | 96 | 1.230 |
Why?
| | HIV Infections | 4 | 2023 | 2588 | 1.040 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 431 | 0.960 |
Why?
| | Anti-Bacterial Agents | 5 | 2024 | 1559 | 0.920 |
Why?
| | Immunity, Humoral | 2 | 2021 | 116 | 0.890 |
Why?
| | Vaccination | 2 | 2021 | 1241 | 0.870 |
Why?
| | Telemedicine | 2 | 2020 | 716 | 0.760 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 28 | 0.700 |
Why?
| | Buprenorphine | 1 | 2023 | 138 | 0.680 |
Why?
| | Pressure Ulcer | 1 | 2020 | 33 | 0.670 |
Why?
| | Liver Diseases, Parasitic | 1 | 2019 | 3 | 0.660 |
Why?
| | Fascioliasis | 1 | 2019 | 7 | 0.650 |
Why?
| | Medical Errors | 1 | 2020 | 100 | 0.650 |
Why?
| | Antibodies, Neutralizing | 1 | 2020 | 231 | 0.640 |
Why?
| | Osteomyelitis | 1 | 2020 | 111 | 0.610 |
Why?
| | Cannabis | 2 | 2023 | 402 | 0.610 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 172 | 0.590 |
Why?
| | Dyspnea | 1 | 2019 | 220 | 0.580 |
Why?
| | Patient Safety | 1 | 2020 | 306 | 0.560 |
Why?
| | Eosinophilia | 1 | 2019 | 185 | 0.560 |
Why?
| | Outpatients | 1 | 2020 | 347 | 0.560 |
Why?
| | RNA, Viral | 1 | 2020 | 587 | 0.550 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 745 | 0.520 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2015 | 262 | 0.430 |
Why?
| | Humans | 24 | 2024 | 125132 | 0.360 |
Why?
| | Myocardial Infarction | 1 | 2015 | 1142 | 0.290 |
Why?
| | Colorado | 3 | 2023 | 4471 | 0.280 |
Why?
| | Stroke | 1 | 2015 | 1098 | 0.260 |
Why?
| | Prevalence | 2 | 2023 | 2488 | 0.250 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 820 | 0.230 |
Why?
| | United States | 5 | 2020 | 13613 | 0.230 |
Why?
| | Endocarditis, Bacterial | 1 | 2024 | 38 | 0.220 |
Why?
| | Ohio | 1 | 2023 | 148 | 0.220 |
Why?
| | Endocarditis | 1 | 2024 | 36 | 0.220 |
Why?
| | Arthritis, Infectious | 1 | 2024 | 53 | 0.220 |
Why?
| | Prosthesis-Related Infections | 1 | 2024 | 75 | 0.210 |
Why?
| | Vancomycin | 1 | 2024 | 77 | 0.210 |
Why?
| | Prospective Studies | 3 | 2021 | 6818 | 0.210 |
Why?
| | Policy | 1 | 2023 | 143 | 0.200 |
Why?
| | Goals | 1 | 2023 | 171 | 0.190 |
Why?
| | Renal Insufficiency | 1 | 2023 | 155 | 0.190 |
Why?
| | Invasive Fungal Infections | 1 | 2021 | 10 | 0.190 |
Why?
| | Aspergillosis | 1 | 2021 | 25 | 0.190 |
Why?
| | Candidiasis | 1 | 2021 | 58 | 0.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 247 | 0.190 |
Why?
| | Young Adult | 3 | 2023 | 11385 | 0.190 |
Why?
| | Vaccines, Synthetic | 1 | 2021 | 130 | 0.180 |
Why?
| | Marijuana Use | 1 | 2023 | 171 | 0.180 |
Why?
| | Immunity | 1 | 2021 | 130 | 0.180 |
Why?
| | History, 17th Century | 1 | 2020 | 19 | 0.180 |
Why?
| | Immunologic Surveillance | 1 | 2020 | 20 | 0.180 |
Why?
| | Quarantine | 1 | 2020 | 26 | 0.170 |
Why?
| | Drug Users | 1 | 2020 | 43 | 0.170 |
Why?
| | Burns | 1 | 2023 | 254 | 0.170 |
Why?
| | Cortical Bone | 1 | 2020 | 19 | 0.170 |
Why?
| | Immunoassay | 1 | 2020 | 104 | 0.170 |
Why?
| | Policy Making | 1 | 2020 | 90 | 0.170 |
Why?
| | Communicable Disease Control | 1 | 2020 | 74 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2021 | 184 | 0.170 |
Why?
| | History, 21st Century | 1 | 2020 | 181 | 0.170 |
Why?
| | Delayed-Action Preparations | 1 | 2020 | 163 | 0.170 |
Why?
| | History, 20th Century | 1 | 2020 | 290 | 0.160 |
Why?
| | Off-Label Use | 1 | 2019 | 56 | 0.160 |
Why?
| | Vulnerable Populations | 1 | 2020 | 156 | 0.160 |
Why?
| | Skilled Nursing Facilities | 1 | 2020 | 133 | 0.160 |
Why?
| | Afghanistan | 1 | 2019 | 130 | 0.160 |
Why?
| | Mortality | 1 | 2020 | 327 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2020 | 222 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 1008 | 0.150 |
Why?
| | Global Health | 1 | 2020 | 350 | 0.150 |
Why?
| | Risk-Taking | 1 | 2020 | 358 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 312 | 0.140 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 612 | 0.140 |
Why?
| | Retrospective Studies | 5 | 2024 | 13708 | 0.140 |
Why?
| | Self Report | 1 | 2021 | 750 | 0.140 |
Why?
| | Acute Kidney Injury | 1 | 2024 | 727 | 0.140 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1183 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2024 | 9790 | 0.130 |
Why?
| | Adult | 4 | 2024 | 33168 | 0.130 |
Why?
| | Male | 5 | 2024 | 60793 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2020 | 673 | 0.120 |
Why?
| | Pilot Projects | 1 | 2019 | 1530 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 1 | 2015 | 273 | 0.120 |
Why?
| | Length of Stay | 1 | 2019 | 1077 | 0.120 |
Why?
| | Chronic Disease | 1 | 2020 | 1684 | 0.120 |
Why?
| | Hospitals | 1 | 2019 | 654 | 0.120 |
Why?
| | Risk Assessment | 1 | 2023 | 3274 | 0.120 |
Why?
| | Female | 5 | 2024 | 64890 | 0.110 |
Why?
| | Health Services Accessibility | 1 | 2020 | 845 | 0.110 |
Why?
| | Mass Screening | 1 | 2020 | 1119 | 0.110 |
Why?
| | Cause of Death | 1 | 2015 | 394 | 0.110 |
Why?
| | Middle Aged | 3 | 2024 | 29112 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2019 | 925 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1191 | 0.100 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 5062 | 0.100 |
Why?
| | Cohort Studies | 1 | 2021 | 5348 | 0.090 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 420 | 0.090 |
Why?
| | Biomarkers | 1 | 2021 | 3736 | 0.090 |
Why?
| | Inflammation | 1 | 2021 | 2612 | 0.090 |
Why?
| | Time Factors | 1 | 2020 | 6780 | 0.080 |
Why?
| | Incidence | 1 | 2015 | 2578 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6936 | 0.070 |
Why?
| | Aged | 3 | 2024 | 20859 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2015 | 4824 | 0.070 |
Why?
| | Debridement | 1 | 2024 | 92 | 0.060 |
Why?
| | Treatment Failure | 1 | 2024 | 348 | 0.050 |
Why?
| | Creatinine | 1 | 2023 | 507 | 0.050 |
Why?
| | Risk Factors | 1 | 2015 | 9549 | 0.050 |
Why?
| | Adolescent | 1 | 2019 | 19411 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2021 | 310 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2021 | 140 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 709 | 0.040 |
Why?
| | Crowding | 1 | 2020 | 40 | 0.040 |
Why?
| | Frail Elderly | 1 | 2020 | 112 | 0.040 |
Why?
| | Nursing Homes | 1 | 2020 | 150 | 0.040 |
Why?
| | Residence Characteristics | 1 | 2020 | 317 | 0.040 |
Why?
| | Urban Population | 1 | 2020 | 433 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2020 | 314 | 0.030 |
Why?
| | Rural Population | 1 | 2020 | 497 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1379 | 0.030 |
Why?
| | Public Health | 1 | 2020 | 493 | 0.030 |
Why?
| | Quality of Life | 1 | 2021 | 2580 | 0.020 |
Why?
|
|
Krsak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|